GSK, Cytokinetics Development Plan For Ispinesib Includes Dozens Of Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Several Phase II trials are proceeding studying the kinesin spindle protein inhibitor in breast, ovarian, prostate and melanoma cancers.
You may also be interested in...
As Amgen Waits, Cytokinetics Ends Year With Cash Aplenty For Heart Trial
CK-542 center stage for now; ispinesib strategy includes chemo-naive patients.
As Amgen Waits, Cytokinetics Ends Year With Cash Aplenty For Heart Trial
CK-542 center stage for now; ispinesib strategy includes chemo-naive patients.
Amgen And Cytokinetics Partner On Novel Heart Failure Treatments
Deal could be worth more than $725 million.